Acetazolamide
Therapeutic Category
- Anti-glaucoma, Diuretic
Innovator Brand
GMP
DMF
Filed
![USDMF Assessed USDMF Assessed](https://www.ctxls.com/wp-content/uploads/2022/10/USDMF-assessed.png)
![CEP CEP](https://www.ctxls.com/wp-content/uploads/2022/10/CEP.png)
![NMPA NMPA](https://www.ctxls.com/wp-content/uploads/2022/10/NMPA.png)
Under Filing
Sample
Indication
Acetazolamide is a diuretic medication that treats swelling caused by heart disease. It works by helping your body make more pee so you can lose salt and excess water from your body. It can also treat seizures, certain types of glaucoma and prevent symptoms of altitude sickness. Acetazolamide is a first generation carbonic anhydrase inhibitor and it decreases the ocular fluid and osmolality in the eye to decrease intraocular pressure.
CTX Lifesciences, is one of the leading Active Pharmaceutical Ingredients ( API ) manufacturer and supplier globally for Acetazolamide API from India. We are a leading exporter of Acetazolamide API with Cas #59-66-5. We are a trusted supplier with API exports in more than 87 Countries including the US, Europe, Brazil, Latin America, China, Korea,Iran, Middle East and other emerging markets.
CTX Lifesciences is one of the leading API manufacturer & supplier of Acetazolamide API with Cas #59-66-5 from India. This product is provided from our GMP compliant plant with product made under complete cGMP conditions. It is provided with documentation support and available with Drug Master File(DMF). Our manufacturing plant at Surat has accreditation by US-FDA, EDQM, EMA, ANVISA, KFDA, MOH IRAN, Health Canada & Russian Authorities.
CTX also offers other Diuretics as mentioned below.
Within Ophthalmic Therapeutic Segment CTX Lifesciences also offer Oxymetazoline HCl API whose end used is as eyedrops to treat eye redness due to minor irritation.
Disclaimer: CTX Lifesciences respects patent laws and conventions of pharmaceuticals as applicable in different countries.
API/Substances covered by patent are not offered to the countries where the patent law is in force. However, the final responsibility lies with the customer.